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THE ROLE OF LOW MOLECULAR WEIGHT HEPARIN 
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SUMMARY – Th e aim of the study was to establish the importance of low molecular weight 
heparin (LMWH) treatment for good pregnancy outcome in patients with hereditary thrombophilia. 
Th is retrospective study included 70 patients with inherited thrombophilia who gave birth at Zagreb 
University Hospital Center in the period from January 2014 to January 2015. Fifty-seven women 
were treated and 13 women were not treated with LMWH. Perinatal outcome was signifi cantly better 
in women with hereditary thrombophilia who were treated with heparin during pregnancy as com-
pared with women without LMWH (p=0.006). Regardless of heparin therapy, patients with heredi-
tary thrombophilia alone had a signifi cantly better perinatal outcome as compared with women who, 
along with hereditary thrombophilia, had a history of habitual abortions (p=0.035) or intrauterine 
fetal death (p=0.033). Women treated with heparin had better perinatal outcome if they were without 
a history of recurrent or non-recurrent fetal loss (p=0.088). In the group without LMWH, perinatal 
outcome was signifi cantly better in women with no history of habitual abortions as compared with 
women with recurrent miscarriages (p=0.047). Administration of LMWH is justifi ed in women with 
hereditary thrombophilia and a history of adverse perinatal outcome.
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Introduction
Th rombophilias are inherited or acquired condi-
tions that create a hypercoagulable state which predis-
poses the individual to thromboembolism1-3. Inherited 
defects related to thrombosis include the G1691A 
mutation in the factor V gene, the G20210A mutation 
in the prothrombin gene, the C677T mutation and the 
A1298C mutation in the methylenetetrahydrofolate 
reductase (MTHFR) gene, antithrombin III, protein 
C and protein S defi ciency4. Th e most entrenched ac-
quired thrombophilia is the antiphospolipid syndrome, 
a non-infl ammatory autoimmune disease character-
ized by the presence of antiphospholipid antibodies. 
Antiphospholipid syndrome can be either primary or 
secondary to another autoimmune disease. Th e overall 
impact of inherited and acquired thrombophilias is 
low in non-pregnant population and the majority of 
patients never experience a thrombotic event. During 
pregnancy, however, the thrombogenic potential of 
these disorders is enhanced because of the hypercoag-
ulable state produced by normal pregnancy-associated 
changes with which the mother’s body adjusts to preg-
nancy and later on to childbirth. Such changes occur 
in the blood fl ow, vascular wall and coagulation factors 
(increased levels of factors VII, VII, X and von Wille-
brand’s factor, decreased activity levels of protein C 
and protein S, and increased activity level of fi brino-
lytic inhibitors)4.
Whereas in recent years numerous studies have es-
tablished the association between acquired thrombo-
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philias and adverse pregnancy outcome5-7, inherited 
thrombophilia and related complications in pregnancy 
still remain debatable8,9. Available evidence does not 
support an association between inherited thrombo-
philia and preeclampsia, fetal growth restriction, or 
abruption, and, in turn, it does not support prophy-
lactic anticoagulation to prevent the possible adverse 
pregnancy outcomes in patients with hereditary 
thrombophilias10. However, adverse medical and ob-
stetric history in patients with inherited thrombophil-
ia requires special caution for good outcome of the 
current pregnancy.
Th e aim of the study was to establish the role of 
low molecular weight heparin (LMWH) in patients 
with inherited thrombophilia for good pregnancy out-
come, with special emphasis on the women with ad-
verse obstetric history, and to identify the common 
types of mutation in the study group.
Patients and Methods
Th is retrospective epidemiological study was con-
ducted at the State Referral Center for Diabetes in 
Pregnancy, Zagreb University Hospital Center, Za-
greb, Croatia, during the period from January 2014 to 
January 2015. Th e study included 70 patients diag-
nosed with hereditary thrombophilia. All enrolled pa-
tients delivered in our hospital but the majority of 
them had their regular examinations and treatment 
provided by their physicians in primary or secondary 
health care centers. Patients were classifi ed into two 
groups: 57 women with hereditary thrombophilia that 
were treated with LMWH and 13 women not treated 
with LMWH despite the diagnosis of inherited 
thrombophilia. Patient characteristics including de-
mographics, obstetric and medical history were ob-
tained from patients at the hospital visit and entered in 
the database. Data on pregnancy outcomes were ob-
tained from the delivery suite database.
Statistical analysis
All statistical analyses were performed using the 
SPSS for Windows, release 17 (SPSS Inc., Chicago, 
IL, USA). For quantitative measurements (continu-
ous), the mean and standard deviation was calculated. 
For qualitative measurements, absolute frequency was 
calculated and prevalence was expressed as percentage. 
Th e c2-test was used on comparison of qualitative data. 
All the variables collected were statistically analyzed 
and presented descriptively. Inferential statistical anal-
ysis aimed to investigate the relationship between the 
use of LMWH in women with thrombophilic muta-
tions and their perinatal outcome. Th e level of statisti-
cal signifi cance was set at p<0.05.
Results
A total of 70 women with inherited thrombophilia 
who gave birth at the Zagreb University Hospital 
Center were recruited during the study period. Th e 
mean age of study patients was 34.2±4 years, range 20-
45 years. Th e mean body mass index was 25.7 (range 
18-35). Th e minimum number of pregnancies was 1 
Table 1. Demographic characteristics of patients 
with hereditary thrombophilia
Characteristic Patients with HT
Age 
(years; mean ± SD and range)
34.2±4.40 (20.0-45.0)
BMI 
(kg/m²; mean ± SD and range)
25.7±5.21 (18.0-35.0)
Gravidity 
(n; mean ± SD and range)
2.9±1.51 (1.0-9.0)
Parity 
(n; mean ± SD and range)
0.7±0.74 (0.0-2.0)
Abortion 
(n; mean ± SD and range)
1.3±1.36 (0.0-7.0)
HT = hereditary thrombophilia; BMI = body mass index; SD = 
standard deviation; n = number
Table 2. History of comorbidity in patients 
with hereditary thrombophilia
History of comorbidity n (%)
 Primary or secondary infertility









 GDM 8 (11.4)
 T1D 1 (1.4)
 T2D 1 (1.4)
n = number; IVF = in vitro fertilization; PIH = pregnancy induced 
hypertension; PE = preeclampsia; GDM = gestational diabetes 
mellitus; T1D = diabetes mellitus type 1; T2D = diabetes mellitus 
type 2
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and maximum 9, with a mean value of 2.9. Th e mini-
mum number of deliveries was 0 and maximum 2, and 
the mean number of abortions was 1.37 (range 0-7) 
(Table 1).
Six (8.5%) women experienced venous thrombo-
embolism before their pregnancy. Th ese pregnant 
women were found to have a family history of venous 
thromboembolism, myocardial infarction or stroke in 
fi rst-degree relatives younger than 50. Th e prevalence 
of this history was 15.7% (11 patients).
Nine (12.5%) women with inherited thrombophil-
ia had a diagnosis of primary or secondary infertility 
and six (6.6%) of them conceived using in vitro fertil-
ization (IVF). Six (8.5%) patients had hypertensive 
disorders such as gestational hypertension and pre-
eclampsia (50% both), and eight (11.4%) women were 
diagnosed with gestational diabetes (Table 2).
All study women had DNA blood tests that con-
fi rmed gene mutations for hereditary thrombophilia. 
Twenty diff erent combinations of gene mutations were 
identifi ed (Table 3).
Given the high prevalence of diff erent types of mu-
tations in the study group, the mutations were classi-
fi ed as isolated (n=27; 38.6%) and combined (n=43; 
38.7%) (Table 4).
Analysis of medical records found that treatment 
with heparin was based on obstetric and family history, 
as well as on the type of mutation for hereditary 
thrombophilia.
Using Pearson’s c2-test, we analyzed perinatal out-
come in all women with hereditary thrombophilia 
(Table 5), in women with hereditary thrombophilia 
treated with LMWH (Table 6) and in women with 
hereditary thrombophilia not treated with LMWH 
(Table 7).
Table 3. Type of mutation for hereditary thrombophilia in the study group
Mutation n %
PAI 1 homozygous 12 10.8
MTHFR heterozygous (C677T), PAI1 (4G/5G) homozygous 11 9.9
PAI1 heterozygous 10 9.0
PAI1 homozygous, MTHFR homozygous 6 5.4
FVL heterozygous, PAI1 heterozygous 5 4.5
PAI1 heterozygous, MTFHFR heterozygous 5 4.5
FII heterozygous, PAI1 homozygous, MTHFR homozygous 4 3.6
MTHFR homozygous, PAI1 heterozygous 3 2.7
FVL heterozygous 2 1.8
FII heterozygous 2 1.8
PAI1 homozygous, protein S defi ciency 1 0.9
MTHFR homozygous, FVL heterozygous 1 0.9
MTHFR homozygous, PAI1 heterozygous, FVL heterozygous 1 0.9
MTHFR heterozygous, PAI1 homozygous, protein S defi ciency 1 0.9
MTHFR heterozygous 1 0.9
PAI1 heterozygous, MTHFR heterozygous, FVL heterozygous 1 0.9
FVL homozygous, PAI1 heterozygous 1 0.9
FII homozygous, FVL heterozygous, PAI1 homozygous, MTHFR heterozygous 1 0.9
MTHFR heterozygous, PAI1 heterozygous, protein C and protein S defi ciency 1 0.9
Antithrombin III defi ciency, PAI1 heterozygous 1 0.9
Table 4. Classifi cation of mutations in the study group
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Adverse perinatal outcome such as intrauterine 
growth restriction (IUGR), intrauterine fetal death 
(IUFD), placental abruption, abortion and preeclamp-
sia (PE) was observed.
According to study results, patients with hereditary 
thrombophilia that received LMWH had a signifi -
cantly better perinatal outcome as compared with the 
group without LMWH (p=0.006).
Th e abortion rate was lower in the group with 
LMWH; however, this group had a higher incidence 
of placental abruption. Th ere were no signifi cant dif-
ferences according to the type of mutation (isolated 
and combined) and perinatal outcome (p=0.661).
Regardless of LMWH, women without habitual 
abortions had a signifi cantly better perinatal outcome 
as compared with women with recurrent miscarriages 
(with emphasis on recurrent spontaneous abortion) 
(p=0.035). Nevertheless, women with no history of ad-
verse perinatal outcome had a signifi cantly better 
pregnancy outcome as compared with women with a 
history of IUFD (p=0.033). Th e latter group showed a 
higher incidence (15.6%) of placental abruption in the 
observed pregnancy (Table 5).
In the group of women with hereditary thrombo-
philia treated with LMWH, we found no association 
between the type of mutation (isolated or combined) 
and perinatal outcome (p=0.636). In the same group, 
there was no signifi cant diff erence in perinatal out-
come between the women with normal pregnancy 
outcome and those with habitual abortions in previous 
pregnancies (p=0.398). Although there was no signifi -
cant diff erence in perinatal outcome between women 
with normal pregnancy outcome and those with IUFD 
in previous pregnancies (p=0.088), women with IUFD 
in previous pregnancies had a higher incidence of pla-
cental abruption in the observed pregnancy (15.4%) 
(Table 6).
In the group of women with hereditary thrombo-
philia but without LMWH treatment, we found no 
association between the type of mutation (isolated or 
combined) and perinatal outcome (p=0.380). Patients 
with no history of adverse perinatal outcome had a sig-
nifi cantly better perinatal outcome than women with a 
history of recurrent miscarriages (p=0.047). In this 
group, there was no patient with a history of IUFD. 







n % n % n % n % n %
LMWH
treatment
No 7 53.8% 2 15.4% 0 0.0% 4 30.8% 0 0.0%
Yes 47 82.5% 6 10.5% 2 3.5% 1 1.8% 1 1.8%
Type of mutation
Isolated 19 70.4% 4 14.8% 1 3.7% 3 11.1% 0 0.0%
Combined 35 81.4% 4 9.3% 1 2.3% 2 4.7% 1 2.3%
Habitual abortion
No 29 76.3% 7 18.4% 1 2.6% 0 0.0% 1 2.6%
Yes 25 78.1% 1 3.1% 1 3.1% 5 15.6% 0 0.0%
IUFD in previous 
pregnancies
No 45 78.9% 6 10.5% 0 0.0% 5 8.8% 1 1.8%









Type of mutation c2 2.409
Df 4
P 0.661
Habitual abortion c2 10.358
Df 4
P 0.035
IUFD in previous pregnancies c2 10.486
Df 4
P 0.033
HT = hereditary thrombophilia; IUGR = intrauterine growth re-
striction; PE = preeclampsia; n = number; LMWH = low molecular 
weight heparin; IUFD = intrauterine fetal death
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Unfortunately, the number of cases in this group was 
too small to obtain meaningful data (Table 7).
Discussion
Th rombophilia in mothers, in addition to natural 
hemostatic changes in every pregnancy, also changes 
placental circulation11,12. Th romboses of maternal pla-
centa may cause complications such as preeclampsia 
and IUGR, as well as more serious complications such 
as miscarriage, placental abruption and IUFD. Nu-
merous studies have evaluated the correlation between 
thrombophilia and pathologic perinatal outcome. 
Even though some retrospective studies argue there is 
a link between certain mutations (heterozygous factor 
V Leiden, heterozygous prothrombin gene, protein C 
and S defi ciency) and missed abortions after 10 weeks 
of gestation, recurrent miscarriages and IUFD after 20 
weeks of gestation, the majority of prospective studies 
deny this causal connection13-15.
Our study included a heterogeneous group of 
women of diff erent age groups, diff erent family and 
personal history, and diff erent reasons for genetic test-
ing for hereditary thrombophilia. Diff erent widespread 
mutations and their combinations found in our geo-
graphical area refl ected in our study group, with a pre-
dominance of so-called ‘mild mutations’ such as PAI1 
and MTHFR, and a lesser percentage of ‘severe muta-
tions’ such as factor V Leiden and factor II mutations. 
Despite the already inveterate opinion that hereditary 
thrombophilia has a negligible impact on perinatal 
outcome, women in our study that were administered 
LMWH had a statistically much better perinatal out-
come than women that did not receive this therapy, 
irrespective of the mutation type (p=0.006). Women 
treated with heparin experienced a lower percentage of 
miscarriages; however, more cases of placental abrup-
tion were recorded in this group. Furthermore, an un-
fortunate outcome of previous pregnancies (e.g., recur-
rent miscarriages, IUFD) also led to worse perinatal 
outcome of the observed pregnancies. It is important 
to highlight that all the observed women with heredi-
tary thrombophilia and recurrent miscarriages that 
were not treated with heparin had a statistically worse 
perinatal outcome as compared with women who were 
not treated with heparin either but had unremarkable 
obstetric history.
Th is study results supported the Royal College of 
Obstetricians and Gynaecologists Green-top guide-
lines, clearly stressing the importance of LMWH for 
better perinatal outcome in pregnant women with he-
Table 6. Perinatal outcome in women with hereditary thrombophilia treated with low molecular weight heparin 
(N=57)







n % n % n % n % n %
Type of mutation
Isolated 18 78.3% 3 13.0% 1 4.3% 1 4.3% 0 0.0%
Combined 29 85.3% 3 8.8% 1 2.9% 0 0.0% 1 2.9%
Habitual abortion
No 25 78.1% 5 15.6% 1 3.1% 0 0.0% 1 3.1%
Yes 22 88.0% 1 4.0% 1 4.0% 1 4.0% 0 0.0%
IUFD in previous 
pregnancies
No 38 86.4% 4 9.1% 0 0.0% 1 2.3% 1 2.3%
Yes 9 69.2% 2 15.4% 2 15.4% 0 0.0% 0 0.0%




Type of mutation c2 2.549
Df 4
P 0.636
Habitual abortion c2 4.060
Df 4
P 0.398
IUFD in previous pregnancies c2 8.095
Df 4
P 0.088
HT = hereditary thrombophilia; IUGR = intrauterine growth re-
striction; PE = preeclampsia; n = number; LMWH = low molecular 
weight heparin; IUFD = intrauterine fetal death
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Table 7. Perinatal outcome in women with hereditary thrombophilia without low molecular weight heparin treatment 
(N=13)







n % n % n % n % n %
Type of mutation
Isolated 1 25.0% 1 25.0% 0 0.0% 2 50.0% 0 0.0%
Combined 6 66.7% 1 11.1% 0 0.0% 2 22.2% 0 0.0%
Habitual
abortion
No 4 66.7% 2 33.3% 0 0.0% 0 0.0% 0 0.0%
Yes 3 42.9% 0 0.0% 0 0.0% 4 57.1% 0 0.0%
IUFD in previous 
pregnancies
No 7 53.8% 2 15.4% 0 0.0% 4 30.8% 0 0.0%
Yes 0 0.0% 0 0.0% 0 0.0% 0 0.0% 0 0.0%




Type of mutation c2 1.935
Df 2
P 0.380
Habitual abortion c2 6.102
Df 2
P 0.047
HT = hereditary thrombophilia; IUGR = intrauterine growth re-
striction; PE = preeclampsia; n = number; LMWH = low molecular 
weight heparin; IUFD = intrauterine fetal death
reditary thrombophilia and pathologic perinatal out-
comes in previous pregnancies, especially recurrent 
trimester II miscarriages or IUFD16.
It is concluded that, regardless of the mutation 
type, hereditary thrombophilia, in addition to compli-
cated obstetric history, requires and justifi es LMWH 
therapy administration for the purpose of a favorable 
perinatal outcome. Th is is especially true for patients 
with a complicated family history.
Th rombophilia is a widespread gene mutation, 
mostly detected incidentally when one’s clinical fea-
tures are provoked by a state of hypercoagulability, 
such as pregnancy. Recurrent pathologic outcomes of 
pregnancies in mutation-carrying women indicate the 
body’s struggle to adjust to the new setting. Numerous 
contradictory results of various studies on the throm-
bophilia eff ect on perinatal outcome can be ascribed to 
small test groups, diff erent diagnostic criteria and pre-
dominantly retrospective study design. Studies on 
greater test groups are needed to clarify the real eff ect 
of certain mutations on pregnancies. Administration 
of heparin can help the body fi ght for a better perinatal 
outcome, especially in women who have already lost 
the battle in past pregnancies. According to our results, 
LMWH proved to be the treatment of choice in pa-
tients with adverse pregnancy events in which throm-
bophilic mutations were identifi ed.
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Sažetak
VAŽNOST PRIMJENE NISKOMOLEKULARNOG HEPARINA 
KOD TRUDNICA S NASLJEDNOM TROMBOFILIJOM ZA DOBAR PERINATALNI ISHOD
V. Sokol, M. Ivanišević, M. Herman i J. Đelmiš
Cilj ove studije bio je ustanoviti komplikacije trudnoće i važnost primjene niskomolekularnog heparina za poboljšanje 
perinatalnog ishoda kod trudnica s nasljednom trombofi lijom. Retrospektivno su analizirani podatci 70 trudnica s dokaza-
nom hereditarnom trombofi lijom i urednom ili opterećenom opstetričkom anamnezom koje su porođene u Klinici za ženske 
bolesti i porođaje u razdoblju od siječnja 2014. do siječnja 2015. Njih 57 liječeno je niskomolekularnim heparinom, dok kod 
ostalih 13 žena nije provedena antikoagulantna terapija. Ispitanice s nasljednom trombofi lijom koje su tijekom trudnoće 
uzimale heparinsku terapiju imale su statistički značajno bolji perinatalni ishod u odnosu na ispitanice s nasljednom trom-
bofi lijom bez antikoagulantne terapije (p=0,006). Ispitanice s hereditarnom trombofi lijom i urednom opstetričkom anamne-
zom imale su statistički značajno bolji perinatalni ishod u odnosu na ispitanice s trombofi lijom i prethodnim habitualnim 
pobačajima (p=0,035) ili intrauterinom smrti čeda (p=0,033). Ispitanice s hereditarnom trombofi lijom i urednim prethodnim 
trudnoćama koje su liječene heparinom imale su nešto bolji perinatalni ishod u odnosu na skupinu s trombofi lijom i prethod-
nim mors fetus in utero kod kojih je također primjenjivana antikoagulantna terapija (p=0,088). U skupini ispitanica s heredi-
tarnom trombofi lijom a bez heparinske terapije, ispitanice bez habitualnih pobačaja u anamnezi imale su statistički značajno 
bolji perinatalni ishod u odnosu na trudnice s habitualnim pobačajima (p=0,047). Primjena niskomolekularnog heparina za 
bolji perinatalni ishod opravdana je kod trudnica s nasljednom trombofi lijom i opterećenom opstetričkom anamnezom.
Ključne riječi: Trombofi lija, nasljedna; Trudnoća; Heparin, niskomolekularni; Trudnoća, ishod
